Table 3.
Results of the fixed-effect direct, Bucher indirect and NMA comparisons
| Comparison |
HbA1c |
Weight (kg) |
Hypoglycaemia |
|||
|---|---|---|---|---|---|---|
| NMA (95% CrI) | Direct/Bucher indirect (95% CI) | NMA (95% CrI) | Direct/Bucher indirect (95% CI) | NMA (95% CrI) | Direct/Bucher indirect (95% CI) | |
| |
WMD v placebo |
Direct comparison |
WMD v placebo |
Direct comparison |
OR v placebo |
Direct comparison |
| DPP-4 v placebo |
-0.56 (-0.70, -0.41)† |
-0.56 (-0.70, -0.41)* |
0.57 (0.09, 1.06)† |
0.57 (0.09, 1.05)* |
1.87 (0.82, 4.72) |
1.8 (0.78, 4.17) |
| GLP-1 v placebo |
-0.80 (-1.04, -0.56)† |
-0.79 (-1.02, -0.55)* |
-0.65 (-1.37, 0.07) |
-0.65 (-1.37, 0.07) |
10.89 (4.24, 38.28)† |
10.05 (3.60, 28.06)* |
| SGLT2 v placebo |
-0.69 (-0.86, -0.52)† |
-0.69 (-0.86, -0.52)* |
-1.54 (-2.16, -0.92)† |
-1.54 (-2.16, -0.92)* |
1.75 (0.67, 4.89) |
1.71 (0.66, 4.48) |
| |
WMD head-to-head |
Bucher indirect comparison |
WMD head-to-head |
Bucher indirect comparison |
OR head-to-head |
Bucher indirect comparison |
| GLP-1 v DPP-4 |
-0.24 (-0.52, 0.04) |
-0.23 (-0.50, 0.04) |
-1.23 (-2.09, -0.36)† |
-1.22 (-2.09, -0.35)* |
5.89 (1.56, 26.06)† |
5.58 (1.49, 20.99)* |
| SGLT2 v DPP-4 |
-0.13 (-0.35, 0.09) |
-0.13 (-0.35, 0.09) |
-2.11 (-2.90, -1.33)† |
-2.11(-2.90, -1.33)* |
0.94 (0.25, 3.50) |
0.95 (0.27, 3.37) |
| SGLT2 v GLP-1 |
0.11 (-0.18, 0.40) |
0.10 (-0.19, 0.39) |
-0.89 (-1.84, 0.07) |
-0.89 (-1.84, 0.06) |
0.16 (0.03, 0.65)† |
0.17 (0.04, 0.69)* |
| |
WMD v baseline |
WMD v baseline |
Probability of hypoglycaemia |
|||
| placebo |
0.05 (-0.10, 0.20) |
N/A |
-0.48 (-0.78, -0.18)† |
N/A |
3.99% (2.30%, 6.85%) |
N/A |
| DPP-4 |
-0.51 (-0.72, -0.30)† |
N/A |
0.09 (-0.47, 0.66) |
N/A |
7.23% (2.75%, 18.67%) |
N/A |
| GLP-1 |
-0.75 (-1.03, -0.47)† |
N/A |
-1.13 (-1.91, -0.35)† |
N/A |
31.38% (13.00%, 64.10%) |
N/A |
| SGLT2 |
-0.64 (-0.87, -0.42)† |
N/A |
-2.02 (-2.71, -1.33)† |
N/A |
6.81% (2.33%, 19.04%) |
N/A |
| |
Model parameter results |
|
||||
| DIC (WinBUGs) |
-10.36 |
N/A |
13.07 |
N/A |
72.301 |
N/A |
| Average resdev | 1.37 | N/A | 1.14 | N/A | 2.25 | N/A |
*Statistically significant result (p < 0.05); †statistically significant based on 95% CrI; CI, confidence interval; CrI, credible interval; DIC, deviance information criterion; DPP-4, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like peptide-1 analogues; OR, odds ratio; NMA, network meta-analysis; resdev, residual deviance; SGLT2, sodium glucose co-transporter 2 inhibitors; WMD, weighted mean difference.